These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29861037)

  • 1. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 2. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
    Vu TT; Gooderham M; Papp K
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis.
    Martínez-Doménech Á; García-Legaz-Martínez M; Magdaleno-Tapial J; Giácaman M; Hernández-Bel P; Pérez-Ferriols A
    Dermatol Online J; 2019 Apr; 25(4):. PubMed ID: 31046917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ixekizumab-induced paradoxical pustular reaction successfully treated with guselkumab.
    Hlaca N; Zagar T; Kastelan M; Brajac I; Prpic-Massari L
    Clin Exp Dermatol; 2021 Dec; 46(8):1572-1573. PubMed ID: 34028847
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 9. Ixekizumab for the treatment of psoriasis: an update on new data since first approval.
    Blegvad C; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2019 Feb; 15(2):111-121. PubMed ID: 30589394
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
    Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple paradoxical reactions during ixekizumab therapy.
    Pirro F; Caldarola G; De Simone C; Moretta G; Giovanardi G; Peris K
    Dermatol Ther; 2019 May; 32(3):e12852. PubMed ID: 30747476
    [No Abstract]   [Full Text] [Related]  

  • 13. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 15. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 16. Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.
    Giunta A; Ventura A; Chimenti MS; Bianchi L; Esposito M
    Drug Des Devel Ther; 2017; 11():1643-1651. PubMed ID: 28652702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
    Zachariae C; Gordon K; Kimball AB; Lebwohl M; Blauvelt A; Leonardi C; Braun D; McKean-Matthews M; Burge R; Cameron G
    J Am Acad Dermatol; 2018 Aug; 79(2):294-301.e6. PubMed ID: 29653208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab associated with flares of psoriatic arthritis.
    Stamell EF; Kutner A; Viola K; Cohen SR
    JAMA Dermatol; 2013 Dec; 149(12):1410-3. PubMed ID: 24132520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.
    Umezawa Y; Torisu-Itakura H; Morisaki Y; ElMaraghy H; Nakajo K; Akashi N; Saeki H;
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):568-576. PubMed ID: 30325534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ixekizumab in a Real-Life Practice: A Retrospective Bicentric Study.
    Magdaleno-Tapial J; Carmena-Ramón R; Valenzuela-Oñate C; Ortiz-Salvador JM; Sabater-Abad J; Hernández-Bel P; Gimeno-Carpio E; Sánchez-Carazo JL; Pérez-Ferriols A
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):585-589. PubMed ID: 31006480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.